Avenue Therapeutics, Inc. (NASDAQ:ATXI) Short Interest Down 35.2% in February

Avenue Therapeutics, Inc. (NASDAQ:ATXIGet Free Report) was the recipient of a significant drop in short interest in the month of February. As of February 28th, there was short interest totalling 59,700 shares, a drop of 35.2% from the February 13th total of 92,200 shares. Based on an average daily volume of 376,300 shares, the days-to-cover ratio is currently 0.2 days. Approximately 3.4% of the company’s shares are short sold.

Avenue Therapeutics Stock Up 9.7 %

Shares of ATXI stock opened at $0.85 on Friday. The stock has a 50-day moving average price of $1.41 and a 200 day moving average price of $1.91. The firm has a market cap of $1.74 million, a price-to-earnings ratio of 0.05 and a beta of -0.29. Avenue Therapeutics has a 12 month low of $0.72 and a 12 month high of $12.75.

Institutional Trading of Avenue Therapeutics

An institutional investor recently bought a new position in Avenue Therapeutics stock. Boothbay Fund Management LLC acquired a new position in Avenue Therapeutics, Inc. (NASDAQ:ATXIFree Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 41,089 shares of the company’s stock, valued at approximately $82,000. Boothbay Fund Management LLC owned 2.00% of Avenue Therapeutics as of its most recent SEC filing. 17.34% of the stock is owned by hedge funds and other institutional investors.

Avenue Therapeutics Company Profile

(Get Free Report)

Avenue Therapeutics, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders.

Featured Stories

Receive News & Ratings for Avenue Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avenue Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.